A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
doi: https://doi.org/10.1101/2022.07.15.22277670

Article usage

Article usage: July 2022 to December 2024

AbstractFullPdf
Jul 2022106512413
Aug 202226225107
Sep 202263224232
Oct 2022440283284
Nov 2022517727261
Dec 202230151148
Jan 202348668221
Feb 202337158130
Mar 20233252986
Apr 20232212655
May 20231233935
Jun 20231323639
Jul 20231002012
Aug 20231022025
Sep 20231052332
Oct 20231103421
Nov 2023851517
Dec 2023731619
Jan 2024811719
Feb 2024791423
Mar 2024471411
Apr 2024631627
May 202450515
Jun 2024591113
Jul 2024481616
Aug 202444512
Sep 202481645
Oct 202436834
Nov 202460715
Dec 2024311
Back to top
Posted January 12, 2023.
Download PDF

Supplementary Material

Data/Code
Email
A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area